CYCLOSPORIN-A IN CADAVERIC ORGAN-TRANSPLANTATION
CYCLOSPORIN-A IN CADAVERIC ORGAN-TRANSPLANTATION
复制标题
DOI：
10.1136/bmj.282.6268.934
复制
发表时间：
1981-01-01
影响因子：
--
通讯作者：
WILLIAMS, R
中科院分区：
文献类型：
--
作者：
CALNE, RY;WHITE, DJG;WILLIAMS, R
使用环孢菌素A（CyA）的协议，旨在避免肾毒性的影响，导致一年的生存率为86%的受体肾移植从不匹配的尸体供体。该药物还能控制肝脏和胰腺移植物的排斥反应。这是可能的，改变患者最初治疗CyA硫唑嘌呤和皮质类固醇，反之亦然，从而扩大了潜在的价值CyA在器官移植。在34例肾移植受者中，29例目前仅接受CyA作为免疫抑制剂治疗。12例患者从未需要任何辅助类固醇治疗。这些结果表明，CyA是一种有效的免疫抑制剂，如果小心使用，副作用不一定很严重。
The use of cyclosporin A (CyA) with a protocol designed to avoid the effects of nephrotoxicity resulted in a one-year survival of 86% in recipients of renal allografts from unmatched cadaveric donors. The drug also controlled rejection of liver and pancreatic allografts. It was possible to change patients initially treated with CyA to azathioprine and corticosteroids and vice versa, thus enlarging the potential value of CyA in organ allografting. Of 34 recipients of renal allografts, 29 were currently receiving only CyA as immunosuppressive treatment. Twelve patients never required any adjuvant steroid treatment. These results suggest that CyA is an effective immunosuppressant, and if used with care side effects need not be severe.